Document is current
Any future updates will be listed below
-
Authors
Schranner, Daniela https://orcid.org/0000-0003-2316-318X
Wackerhage, Henning
Weinisch, Patrick
Schlegel, Jürgen
Bremer, Stephanie
Scherr, Johannes
Römisch-Margl, Werner
Riermeier, Annett
Zelger, Otto
Stöcker, Fabian
Artati, Anna
Witting, Michael
Krumsiek, Jan
Halle, Martin
Schönfelder, Martin
Kastenmüller, Gabi https://orcid.org/0000-0002-2368-7322
-
Funding
Funding for this research was provided by:
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 15 February 2026
First Online: 9 March 2026
Declarations
:
: This study conforms to the Declaration of Helsinki for use of human subjects and tissue and was approved by the medical ethics committee of the Technical University of Munich (356/17S). Participants were fully informed of the nature and possible risks of the study before they gave their written informed consent.
: Participants were fully informed that their data will be made publicly available to the scientific community after anonymization.
: GK is inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS (central nervous system) diseases and holds equity in Chymia LLC. The remaining authors declare that they have no competing interests.
